Who has been buying LivesMed stock?

1 distinct insiders have filed 1 disclosed insider purchases in LivesMed (491000), most recently on 2026-07-03. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does LivesMed have?

LivesMed has 1 buy-side and 0 sell-side disclosures on record, covering ₩231K ($161) in total reported value, spanning 2025-12-29 to 2026-07-03.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

LivesMed 491000

Company

리브스메드LivesMed

Insiders

Buys

Total Value

₩231K ($161)

Avg Return

+87.24%

Last Filing

2026-07-03

LivesMed (491000) has 1 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩231K ($161) in reported transaction value. The earliest filing StockDrifts holds for LivesMed is dated 2025-12-29; the most recent is 2026-07-03. Across these filings the average return since disclosure is +87.24%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-07-03	BUY	주식매수청구권 행사	이동욱 Dongwook Lee	Managing Director	51.0K	₩34,250	+10.5%	₩1.7B ($1.2M)
2026-07-03	BUY	주식매수청구권 행사	장동규 Jang Dong-gyu	Managing Director	65.0K	₩34,250	+10.5%	₩2.2B ($1.5M)
2026-07-03	BUY	주식매수청구권 행사	김욱은 Kim Wook-eun	Managing Director	51.0K	₩34,250	+10.5%	₩1.7B ($1.2M)
2026-07-03	BUY	주식매수청구권 행사	오세윤 Oh Se-yoon	vice president	10.6K	₩34,250	+10.5%	₩363M ($252K)
2026-04-15	BUY	신규선임	김재헌 Jaeheon Kim	moving	2.0K	₩61,800	+1.3%	₩124M ($86K)
2026-01-21	BUY	PROGRAM	이동욱 Dongwook Lee	Managing Director	3.0K	₩57,200	+51.4%	₩172M ($119K)
2026-01-21	BUY	PROGRAM	김욱은 Kim Wook-eun	Managing Director	3.0K	₩57,200	+51.4%	₩172M ($119K)
2026-01-21	BUY	PROGRAM	정순용 Jeong Soon-yong	moving	3.0K	₩57,200	+51.4%	₩172M ($119K)
2026-01-21	BUY	PROGRAM	장동규 Jang Dong-gyu	Managing Director	3.0K	₩57,200	+51.4%	₩172M ($119K)
2026-01-21	BUY	PROGRAM	오세윤 Oh Se-yoon	vice president	3.0K	₩57,200	+51.4%	₩172M ($119K)
2026-01-21	BUY	PROGRAM	배동환 Donghwan Bae	Managing Director	135.0K	₩57,200	+51.4%	₩7.7B ($5.4M)
2025-12-29	BUY	Market Buy	정순용 Jeong Soon-yong	moving	5	₩46,250	+87.2%	₩231K ($161)

Frequently asked questions

Who has been buying LivesMed stock?: 1 distinct insiders have filed 1 disclosed insider purchases in LivesMed (491000), most recently on 2026-07-03. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does LivesMed have?: LivesMed has 1 buy-side and 0 sell-side disclosures on record, covering ₩231K ($161) in total reported value, spanning 2025-12-29 to 2026-07-03.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.